Dallas, TX (PRWEB) September 28, 2012
The Pradaxa Resource Center, a patient advocacy group, is alerting patients who have been prescribed the blood thinner Pradaxa that the drug has been linked to severe internal bleeding. Also, a federal judge recently ruled that those injured may proceed with lawsuits.
Anyone affected by internal bleeding or the loss of a loved one from Pradaxa is urged to speak with a lawyer about their legal rights as soon as possible.
Pradaxa is a popular anticoagulant drug prescribed to patients with atrial fibrillation to prevent blood clots and strokes. Since it was released in 2010, it has earned Boehringer Ingelheim over $1 billion with use in over 70 countries, according to The Wall Street Journal on April 24, 2012.
On December 7, 2011, however, the FDA warned that it was investigating Pradaxa after receiving more injury and death reports than expected. According to USA Today on August 19, 2012, 3,781 side effects and 542 deaths were reported among users in 2011, which led all other medications. On September 24, 2012, researchers at the University of Pécs in Hungary warned that those taking drugs like Pradaxa were three times as likely to have a bleeding event.
Although all anticoagulants carry a risk of internal bleeding, most have a reversal agent available to doctors in emergency. A March 6, 2012 report by the Journal of Neurosurgery detailed a specific case and complaints by doctors that once Pradaxa causes internal bleeding in a patient, there is very little they can do to stop it.
Due to the number of Pradaxa lawsuits expected from those injured, a central court was recently established in Illinois to handle the claims. The case is known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois. On September 5, 2012, the U.S. Panel on Multidistrict Litigation indicated that more than 100 Pradaxa lawsuits have been filed so far.
On July 25th, Judge David Herndon denied an attempt by Boehringer Ingelheim to dismiss the cases. Judge Herndon also set an initial hearing for October 3rd and indicated trials should start in 18 to 24 months.
Anyone affected by Pradaxa internal bleeding is urged to speak with a lawyer about their legal options as soon as possible. Due to the specialized nature of these federal MDL cases, the Pradaxa Resource center only recommends lawyers who are already handling Pradaxa lawsuits.
To speak with a lawyer, or for more information on the research, warnings, side effects and legal options relating to the drug Pradaxa, visit http://www.Pradaxa-lawsuits.org.